主要促进因子超家族结构域蛋白2a在脑病中的作用研究进展

doi:10.3969/j.issn.1004-616x.2023.05.013

摘要/Abstract

摘要： 主要促进因子超家族结构域蛋白2a(MFSD2A)在神经系统疾病和脑血管疾病中的作用近年来日益受到关注，它被认为是突破血脑屏障的关键蛋白。MFSD2A能维持和调节血脑屏障(BBB)的完整性和通透性，对出现BBB损伤症状的多种疾病具有治疗效果，能转运二十二碳六烯酸入脑，预防和治疗阿尔茨海默病、常染色体隐性遗传原发性小头畸形等疾病；也能作为载体蛋白或调节BBB囊泡转运输送药物透过BBB治疗其他脑病。本文综述了目前MFSD2A在阿尔茨海默病、脑卒中、小头畸形等脑病中作用的研究现状，旨在为MFSD2A的基础研究和临床应用提供科学参考。

关键词: MFSD2A, 二十二碳六烯酸, 血脑屏障, 脑病

中图分类号:

皇冯玉, 陈思凯, 卫培峰, 奚苗苗, 董泰玮. 主要促进因子超家族结构域蛋白2a在脑病中的作用研究进展[J]. 癌变·畸变·突变, 2023, 35(5): 400-404.

参考文献

[1] ANDREONE B J, CHOW B W, TATA A, et al. Blood-brain barrier permeability is regulated by lipid transport-dependent suppression of caveolae-mediated transcytosis[J]. Neuron, 2017, 94(3):581-594.e5.
[2] KADRY H, NOORANI B, CUCULLO L. A blood-brain barrier overview on structure, function, impairment, and biomarkers of integrity[J]. Fluids Barriers CNS, 2020, 17(1):69.
[3] 曾茹, 贺桂琼. 包含主要协同转运蛋白超家族结构域蛋白2a的研究进展[J]. 生命科学, 2021, 33(4):419-427.
[4] 朱嘉微, 肖汀. 主要促进因子超家族成员Mfsd2a的研究进展[J]. 癌变·畸变·突变, 2019, 31(1):86-88.
[5] HU C L, TAO L, CAO X Z, et al. The solute carrier transporters and the brain:physiological and pharmacological implications[J]. Asian J Pharm Sci, 2020, 15(2):131-144.
[6] LAW C J, MALONEY P C, WANG D N. Ins and outs of major facilitator superfamily antiporters[J]. Annu Rev Microbiol, 2008, 62:289-305.
[7] NGUYEN L N, MA D L, SHUI G H, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid[J]. Nature, 2014, 509(7501):503-506.
[8] YANG Y R, XIONG X Y, LIU J, et al. Mfsd2a (major facilitator superfamily domain containing 2a) attenuates intracerebral hemorrhage-induced blood-brain barrier disruption by inhibiting vesicular transcytosis[J]. J Am Heart Assoc, 2017, 6(7):e005811.
[9] JUMPER J, EVANS R, PRITZEL A, et al. Highly accurate protein structure prediction with alpha fold[J]. Nature, 2021, 596(7873):583-589.
[10] WANG Z F, ZHENG Y T, WANG F, et al. Mfsd2a and Spns2 are essential for sphingosine-1-phosphate transport in the formation and maintenance of the blood-brain barrier[J]. Sci Adv, 2020, 6(22):eaay8627.
[11] LEI S, LI J, YU J J, et al. Porphyromonas gingivalis bacteremia increases the permeability of the blood-brain barrier via the Mfsd2a/Caveolin-1 mediated transcytosis pathway[J]. Int J Oral Sci, 2023, 15(1):3.
[12] BAZAN N G, MOLINA M F, GORDON W C. Docosahexaenoic acid signalolipidomics in nutrition:significance in aging, neuroinflammation, macular degeneration, Alzheimer's, and other neurodegenerative diseases[J]. Annu Rev Nutr, 2011, 31:321-351.
[13] BALAKRISHNAN J, KANNAN S, GOVINDASAMY A. Structured form of DHA prevents neurodegenerative disorders:a better insight into the pathophysiology and the mechanism of DHA transport to the brain[J]. Nutr Res, 2021, 85:119-134.
[14] CHAN J P, WONG B H, CHIN C F, et al. The lysolipid transporter Mfsd2a regulates lipogenesis in the developing brain[J]. PLoS Biol, 2018, 16(8):e2006443.
[15] 周佳. 寨卡病毒抑制内皮转运体Mfsd2a及其致病机制研究[D]. 北京:北京协和医学院, 2019.
[16] SÁNCHEZ-CAMPILLO M, RUIZ-PASTOR M J, GÁZQUEZ A, et al. Decreased blood level of MFSD2a as a potential biomarker of Alzheimer's disease[J]. Int J Mol Sci, 2019, 21(1):70.
[17] FAKHOURY M. Microglia and astrocytes in Alzheimer's disease:implications for therapy[J]. Curr Neuropharmacol, 2018, 16(5):508-518.
[18] WEI B Z, LI L, DONG C W, et al. The relationship of Omega-3 fatty acids with dementia and cognitive decline:evidence from prospective cohort studies of supplementation, dietary intake, and blood markers[J]. Am J Clin Nutr, 2023, 117(6):1096-1109.
[19] ROUCH L, GIUDICI K V, CANTET C, et al. Associations of erythrocyte omega-3 fatty acids with cognition, brain imaging and biomarkers in the Alzheimer's disease neuroimaging initiative:cross-sectional and longitudinal retrospective analyses[J]. Am J Clin Nutr, 2022, 116(6):1492-1506.
[20] MINTER M R, TAYLOR J M, CRACK P J. The contribution of neuroinflammation to amyloid toxicity in Alzheimer's disease[J]. J Neurochem, 2016, 136(3):457-474.
[21] QU C H, SONG H, SHEN J, et al. Mfsd2a reverses spatial learning and memory impairment caused by chronic cerebral hypoperfusion via protection of the blood-brain barrier[J]. Front Neurosci, 2020, 14:461.
[22] ZOU L, HE J Y, GU L L, et al. Brain innate immune response via miRNA-TLR7 sensing in polymicrobial sepsis[J]. Brain Behav Immun, 2022, 100:10-24.
[23] YI H Y, DUAN Y L, SONG R J, et al. Activation of glucagon-like peptide-1 receptor in microglia exerts protective effects against sepsisinduced encephalopathy via attenuating endoplasmic reticulum stressassociated inflammation and apoptosis in a mouse model of sepsis[J]. Exp Neurol, 2023, 363:114348.
[24] ZHOU S, LI Y H, HONG Y, et al. Puerarin protects against sepsis-associated encephalopathy by inhibiting NLRP3/Caspase-1/GSDMD pyroptosis pathway and reducing blood-brain barrier damage[J]. Eur J Pharmacol, 2023, 945:175616.
[25] QI B, SONG Y, CHEN C, et al. Molecular hydrogen attenuates sepsis-induced cognitive dysfunction through regulation of tau phosphorylation[J]. Int Immunopharmacol, 2023, 114:109603.
[26] ZHONG X L, XIE L L, YANG X L, et al. Ethyl pyruvate protects against sepsis-associated encephalopathy through inhibiting the NLRP3 inflammasome[J]. Mol Med, 2020, 26(1):55.
[27] HE Y J, XU H, FU Y J, et al. Intraperitoneal hypertension, a novel risk factor for sepsis-associated encephalopathy in sepsis mice[J]. Sci Rep, 2018, 8(1):8173.
[28] ACHROL A S, RENNERT R C, ANDERS C, et al. Brain metastases[J]. Nat Rev Dis Primers, 2019, 5:5.
[29] JU X F, MIAO T T, CHEN H Y, et al. Overcoming Mfsd2a-mediated low transcytosis to boost nanoparticle delivery to brain for chemotherapy of brain metastases[J]. Adv Healthc Mater, 2021, 10(9):e2001997.
[30] TIWARY S, MORALES J E, KWIATKOWSKI S C, et al. Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a[J]. Sci Rep, 2018, 8(1):8267.
[31] DARVISH H, ESMAEELI-NIEH S, MONAJEMI G B, et al. A clinical and molecular genetic study of 112 Iranian families with primary microcephaly[J]. J Med Genet, 2010, 47(12):823-828.
[32] CHUA G L, TAN B C, LOKE R Y J, et al. Mfsd2a utilizes a flippase mechanism to mediate omega-3 fatty acid lysolipid transport[J]. Proc Natl Acad Sci U S A, 2023, 120(10):e2215290120.
[33] GUEMEZ-GAMBOA A, NGUYEN L N, YANG H B, et al. Inactivating mutations in MFSD2A, required for omega-3 fatty acid transport in brain, cause a lethal microcephaly syndrome[J]. Nat Genet, 2015, 47(7):809-813.
[34] KHULLER K, YIGIT G, MARTÍNEZ GRIJALVA C, et al. MFSD2Aassociated primary microcephaly-Expanding the clinical and mutational spectrum of this ultra-rare disease[J]. Eur J Med Genet, 2021, 64(10):104310.
[35] ALAKBARZADE V, HAMEED A, QUEK D Q, et al. A partially inactivating mutation in the sodium-dependent lysophosphatidylcholine transporter MFSD2A causes a non-lethal microcephaly syndrome[J]. Nat Genet, 2015, 47(7):814-817.
[36] RAZMARA E, AZIMI H, TAVASOLI A R, et al. Novel neuroclinical findings of autosomal recessive primary microcephaly 15 in a consanguineous Iranian family[J]. Eur J Med Genet, 2020, 63(12):104096.
[37] WOOD C A P, ZHANG J R, AYDIN D, et al. Structure and mechanism of blood-brain-barrier lipid transporter MFSD2A[J]. Nature, 2021, 596(7872):444-448.
[38] HAREL T, QUEK D Q Y, WONG B H, et al. Homozygous mutation in MFSD2A, encoding a lysolipid transporter for docosahexanoic acid, is associated with microcephaly and hypomyelination[J]. Neurogenetics, 2018, 19(4):227-235.
[39] SCALA M, CHUA G L, CHIN C F, et al. Biallelic MFSD2A variants associated with congenital microcephaly, developmental delay, and recognizable neuroimaging features[J]. Eur J Hum Genet, 2020, 28(11):1509-1519.
[40] ZHOU J, CHI X J, CHENG M, et al. Zika virus degrades the ω-3 fatty acid transporter Mfsd2a in brain microvascular endothelial cells and impairs lipid homeostasis[J]. Sci Adv, 2019, 5(10):eaax7142.
[41] YAMAGATA K. Dietary docosahexaenoic acid inhibits neurodegeneration and prevents stroke[J]. J Neurosci Res, 2021, 99(2):561-572.
[42] ZHANG Y, WANG L, PAN Q L, et al. Selective sphingosine-1-phosphate receptor 1 modulator attenuates blood-brain barrier disruption following traumatic brain injury by inhibiting vesicular transcytosis[J]. Fluids Barriers CNS, 2022, 19(1):57.
[43] 胡琼文, 李乐雯, 吴妹, 等. 缺血性脑卒中基于Nrf-2/HO-1上调Mfsd2a表达缓解BCFB损伤研究[J]. 脑与神经疾病杂志, 2022, 30(6):380-384.
[44] ZHAO C S, MA J W, WANG Z, et al. Mfsd2a attenuates blood-brain barrier disruption after sub-arachnoid hemorrhage by inhibiting caveolae-mediated transcellular transport in rats[J]. Transl Stroke Res, 2020, 11(5):1012-1027.
[45] CHEN H, TANG X Q, LI J, et al. IL-17 crosses the blood-brain barrier to trigger neuroinflammation:a novel mechanism in nitroglycerininduced chronic migraine[J]. J Headache Pain, 2022, 23(1):1.